RayKnowChina Research Map
Shortlist0

RecruitingNeuroblastomaPhase 1

Registered title, quoted from ClinicalTrials.gov

TAA06 Injection in the Treatment of Patients With B7-H3-positive Relapsed/ Refractory Neuroblastoma

An open trial on neuroblastoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 2 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 2

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteShandong Cancer Hospital and Institute山东省肿瘤医院JinanHospital page
  2. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05562024, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 1 year to Not stated; sex: all

    Registered eligibility fields

  2. Refractory is defined as a person who is not in remission after at least 4 cycles of chemotherapy (≥ 2 chemotherapeutic drugs, including alkylating agents and platinum)

    Inclusion criterion 6

  3. Karnofsky score (> 16 years) or Lansky score (≤ 16 years) > 60 points

    Inclusion criterion 3

  4. Total bilirubin ≤ 3 × ULN;ALT and AST ≤ 5 × ULN

    Inclusion criterion 11

    Creatinine≤2 ULN

    Inclusion criterion 12

  5. At least one measurable lesion defined by RECISTv1.1 criteria, and at least one lesion that can be irradiated (except bone marrow)

    Inclusion criterion 8

  6. Hepatitis B surface antigen (HBsAg) positive; hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer detection not within the normal reference range; hepatitis C virus (HCV) antibody positive and peripheral blood type C Hepatitis virus (HCV) RNA positive; human immunodeficiency virus (HIV) antibody positive; cytomegalovirus (CMV) DNA positive; syphilis positive

    Exclusion criterion 4

  7. Pregnancy-capable female subjects who plan to become pregnant within 2 years of cell reinfusion; or male subjects whose partners plan to become pregnant within 2 years of cell reinfusion

    Exclusion criterion 10

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05562024, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age ≥ 1 year (including cut-off value), gender is not limited
  • Expected survival time ≥ 3 months
  • Karnofsky score (> 16 years) or Lansky score (≤ 16 years) > 60 points
  • Meet the clinical diagnostic criteria and be diagnosed as recurrent / refractory neuroblastoma. For first-line standard treatment, please refer to the consensus of experts in the diagnosis and treatment of Pediatric Neuroblastoma (Chinese Journal of Pediatric surgery, Volume 36, No. 1, 2015), the guidelines for the diagnosis and treatment of Pediatric Neuroblastoma of 2019 by the Health Commission, and the consensus of experts in the diagnosis and treatment of Pediatric Neuroblastoma (CCCG-NB-2021 Program) (Chinese Journal of Pediatric surgery, Volume 43, No. 7, 2022)
  • Recurrence is defined as the determination of recurrence after remission after at least first-line standard treatment.
  • Refractory is defined as a person who is not in remission after at least 4 cycles of chemotherapy (≥ 2 chemotherapeutic drugs, including alkylating agents and platinum)
  • The tumor tissue samples of the subjects were stained by immunohistochemistry (IHC) to show that the expression intensity of B7-H3 on the surface of tumor cell membranes was 1+ or above, and the proportion of positive staining of tumor cell membranes was ≥1%
  • At least one measurable lesion defined by RECISTv1.1 criteria, and at least one lesion that can be irradiated (except bone marrow)
  • Subjects with lesions only in the bone marrow may also be enrolled (without irradiation)
  • Liver and kidney function, cardiopulmonary function must meet the following requirements:
  • Total bilirubin ≤ 3 × ULN;ALT and AST ≤ 5 × ULN
  • Creatinine≤2 ULN
  • Left ventricular ejection fraction ≥ 50%
  • Blood oxygen saturation ≥ 92%
  • Patients and/or their guardians understand the trial and have signed informed consent

Exclusion Criteria:

  • Patients who were judged by the investigator to require long-term immunosuppressive therapy at the time of screening
  • Cerebrovascular accident or seizure occurred within 6 months before signing the informed consent
  • Malignant tumors other than neuroblastoma, excluding carcinoma in situ
  • Hepatitis B surface antigen (HBsAg) positive; hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer detection not within the normal reference range; hepatitis C virus (HCV) antibody positive and peripheral blood type C Hepatitis virus (HCV) RNA positive; human immunodeficiency virus (HIV) antibody positive; cytomegalovirus (CMV) DNA positive; syphilis positive
  • Serious cardiac disease: including but not limited to unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure (New York Heart Association [NYHA] classification ≥ grade III), severe arrhythmia
  • Unstable systemic disease as judged by the investigator: including but not limited to severe liver, kidney or metabolic disease requiring drug therapy
  • Presence of chronic progressive neurological disease
  • Patients who have not recovered from acute toxic effects of prior treatment
  • Active or uncontrolled infection requiring systemic treatment (except mild urogenital and upper respiratory tract infections)
  • Pregnancy-capable female subjects who plan to become pregnant within 2 years of cell reinfusion; or male subjects whose partners plan to become pregnant within 2 years of cell reinfusion
  • Those who have received CAR-T therapy or other gene-modified cell therapy before screening
  • Participated in other clinical studies within 1 month before screening
  • Subjects screened for evidence of central nervous system involvement
  • For patients with liver metastases, the distribution of liver metastases exceeds 1/2 of the liver
  • According to the judgment of the investigators, it does not meet the situation of cell preparation
  • Other circumstances deemed inappropriate by investigators

Quoted from ClinicalTrials.gov, NCT05562024, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05562024, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05562024